24 citations
,
September 2002 in “Der Urologe” A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
January 2003 in “Natural Science Journal of Xiangtan University” The improved process makes Finasteride suitable for industrial production.
February 1996 in “Clinical Pharmacology & Therapeutics” MK-386 reduces sebum DHT levels.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
May 2024 in “Clinical and experimental optometry” 14 citations
,
April 2024 in “The Journal of Steroid Biochemistry and Molecular Biology” 5α-reductases increase epitestosterone's effect on androgen receptors.
August 2013 in “Circulation Research” Finasteride reduces heart enlargement and improves heart function.
7 citations
,
July 1995 in “PubMed” Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
July 2025 in “Pharmaceutics” Recombinant Human Annexin A5 may help treat localized scleroderma by reducing skin thickening and inflammation.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
46 citations
,
July 2010 in “Advances in Therapy” SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.
July 2024 in “Reactions Weekly” 23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
20 citations
,
August 2014 in “Talanta” The method effectively measures drug impact on DHT levels in prostate treatments.
35 citations
,
June 2018 in “Urology” The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
6 citations
,
June 2009 in “Journal of Clinical Oncology” 5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.
4 citations
,
July 2020 in “Research Square (Research Square)” The research helps understand how finasteride works and aids drug development.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
10 citations
,
August 1998 in “Journal of Investigative Dermatology” The compounds tested could potentially treat hair loss and alopecia.
November 2007 in “Hospital pharmacy” The conclusion is that healthcare professionals should report adverse drug reactions to improve medication safety and patient care.
3 citations
,
December 2018 in “Biomedical and pharmacology journal/Biomedical & pharmacology journal” Compound 3 protects the heart from damage by activating A1-adenosine receptors.
June 2024 in “Advances in therapy” IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.
15 citations
,
March 2007 in “Hormones and Behavior” Finasteride boosts morphine's pain relief, stops tolerance, and reduces withdrawal in rats.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.